| Literature DB >> 34697596 |
Daniel Meretz1, Martin Seifert1, Viviane Möller1, Christian Georgi1, Hans-Heinrich Minden2, Dirk Große Meininghaus3, Gerhard Janßen4, Anja Haase-Fielitz1,5, Christian Butter1.
Abstract
Entities:
Keywords: COVID-19 lockdown; Fitness tracker; Physical activity; Pulmonary vein isolation
Year: 2021 PMID: 34697596 PMCID: PMC8529324 DOI: 10.1016/j.ijcha.2021.100901
Source DB: PubMed Journal: Int J Cardiol Heart Vasc ISSN: 2352-9067
Baseline characteristics of the study cohort.
| Variables | n = 51 |
|---|---|
| Age (years) | 63.0 (58.0–69.0) |
| Women, n (%) | 20 (39.2%) |
| Body mass index (kg / m2) | 27.8 (25.9–31.1) |
| Antiarrhythmic drugs* after PVI, n (%) | 9 (18%) |
| Paroxysmal AF, n (%) / persistent AF, n (%) | 23 (45%) / 28 (55%) |
| Baseline LVEF (%) | 57 (25–79) |
| Baseline Left atrial diameter (mm) | 40 (13–62) |
| Coronary artery disease, n (%) | 13 (25%) |
| Previous myocardial infarction, n (%) | 3 (6%) |
| Peripheral artery disease, n (%) | 3 (6%) |
| Diabetes, n (%) | 10 (20%) |
| Arterial Hypertension, n (%) | 34 (67%) |
| Stroke, n (%) | 2 (4%) |
| Chronic kidney disease, n (%) | 5 (10%) |
| Type of pulmonary vein isolation | |
| Cryoballoon ablation, n (%) | 34 (67%) |
| Radiofrequency ablation, n (%) | 17 (33%) |
| Time between PVI and first lockdown (days) | 201 (104–238) |
| AFEQT Score*, points | 62.0 (49.0–83.0) |
Antiarrhythmic drugs: flecainide or amiodarone, PVI, pulmonary vein isolation.
Atrial fibrillation (AF); LVEF, left ventricular ejection fraction.
Atrial Fibrillation Effect on Quality-of-Life (AFEQT) questionnaire.
Continuous Variables are reported as median and 25 to 75th interquartile range, Categorical variables are expressed as counts and percentages.
Fig. 1aSteps per day before and during first and second COVID-19 lockdown (boxplots).
Fig. 1bWalking distance per week in kilometre before and during first and second COVID-19 lockdown (boxplots).